In Vitro Activities of Daptomycin, Vancomycin, Linezolid, and Quinupristin-Dalfopristin against Staphylococci and Enterococci, Including Vancomycin- Intermediate and -Resistant Strains

Rybak, Michael J.; Hershberger, Ellie; Moldovan, Tabitha; Grucz, Richard G.

doi:10.1128/aac.44.4.1062-1066.2000

Cited by 328 publications

(235 citation statements)

References 10 publications

Supporting

Mentioning

212

Contrasting

Unclassified

Order By: Relevance

“…Moreover, two clinical isolate strains of vancomycin-resistant S. aureus (VRSA) have been isolated from patients in USA since 2002 [1]. Today, only a few drugs such as linezolid [2], quinupristin/dalfopristin [2] and daptomycin [2] are clinically used for both VRE and MRSA infections. Therefore, the development of novel drugs effective for VRE and MRSA (VRSA) is greatly desired.…”

Section: Introductionmentioning

confidence: 99%

Pargamicin A, a Novel Cyclic Peptide Antibiotic from Amycolatopsis sp.

et al. 2008

View full text Add to dashboard Cite

A novel cyclic peptide antibiotic, pargamicin A was isolated from the culture broth of an actinomycete strain. The producing organism, designated ML1-hF4, was identified as a member of the genus Amycolatopsis. In the course of screening for new antimicrobial substances from microorganisms, we found that an actinomycete strain isolated from a soil collected in Tokyo, Japan, produces a new cyclic peptide antibiotic, which was named pargamicin A (1, Fig. 1). Compound 1 showed strong antibacterial activity against MRSA and VRE.In this paper, we describe the identification of the producing organism, isolation, fermentation, structure elucidation and biological activities of 1. Materials and Methods GeneralOptical rotation was measured with a Perkin-Elmer model 241 polarimeter. UV spectra were recorded with a Hitachi 557 spectrophotometer. The IR spectrum was recorded with a Horiba FT-210 Fourier transform infrared spectrometer. The 1 H-and 13 C-NMR spectra were measured with a JEOL JNM-A500 spectrometer at 24°C using TMS as an internal

show abstract

Section: Introductionmentioning

confidence: 99%

Pargamicin A, a Novel Cyclic Peptide Antibiotic from Amycolatopsis sp.

et al. 2008

View full text Add to dashboard Cite

show abstract

“…Daptomycin and linezolid are newer antimicrobial agents that are active against gram-positive cocci [5,6]. Daptomycin, a lipopeptide, has a spectrum of activity very similar to vancomycin [6].…”

Section: Introductionmentioning

confidence: 99%

“…Daptomycin, a lipopeptide, has a spectrum of activity very similar to vancomycin [6]. Linezolid, has excellent activity against most staphylococci in systemic infections; nevertheless, resistance has begun to emerge [7][8][9].…”

Section: Introductionmentioning

confidence: 99%

In vitro Activity of Daptomycin, Linezolid and Rifampicin on Staphylococcus epidermidis Biofilms

et al. 2011

View full text Add to dashboard Cite

Owing to their massive use, Staphylococcus epidermidis has recently developed significant resistance to several antibiotics, and became one of the leading causes of hospital-acquired infections. Current antibiotics are typically ineffective in the eradication of bacteria in biofilmassociated persistent infections. Accordingly, the paucity of effective treatment against cells in this mode of growth is a key factor that potentiates the need for new agents active in the prevention or eradication of biofilms. Daptomycin and linezolid belong to the novel antibiotic therapies that are active against gram-positive cocci. On the other hand, rifampicin has been shown to be one of the most potent, prevalent antibiotics against S. epidermidis biofilms. Therefore, the main aim of this study was to study the susceptibility of S. epidermidis biofilm cells to the two newer antimicrobial agents previously mentioned, and compare the results obtained with the antimicrobial effect of rifampicin, widely used in the prevention/treatment of indwelling medical device infections. To this end the in vitro activities of daptomycin, linezolid, and rifampicin on S. epidermidis biofilms were accessed, using these antibiotics at MIC and peak serum concentrations. The results demonstrated that at MIC concentration, rifampicin was the most effective antibiotic tested. At peak serum concentration, both strains demonstrated similar susceptibility to rifampicin and daptomycin, with colony-forming units (CFUs) reductions of approximately 3-4 log 10 , with a slightly lower response to linezolid, which was also more strain dependent. However, considering all the parameters studied, daptomycin was considered the most effective antibiotic tested, demonstrating an excellent in vitro activity against S. epidermidis biofilm cells. In conclusion, this antibiotic can be strongly considered as an acceptable therapeutic option for S. epidermidis biofilm-associated infections and can represent a potential alternative to rifampicin in serious infections where rifampicin resistance becomes prevalent.

show abstract

“…Gram pozitif aerop ve anaerop bakteri grupları üzerine hızlı bakterisidal etkinliğe sahiptir. Metisiline dirençli stafilokok türleri, glikopeptidlere orta duyarlı S. aureus, penisilin dirençli Streptococcus pneumoniae ve vankomisine dirençli enterokokları (VRE) da içine alan geniş çapta etkinliği vardır (7)(8)(9)(10) . Daptomisin, oligorimerizasyon ile hücre zarı bütünlüğünü bozar, depolarizasyon sonucu sitoplazma zarı işlevini kaybeder ve hücre hızla ölür.…”

Section: Introductionunclassified

In Vitro Daptomycin and Linezolid Susceptibility Profiles of Enterococcus faecium and Enterococcus faecalis Strains Isolated from Blood Cultures

Öcal¹,

Gürbüz²,

Dansuk³

et al. 2017

TMCD

View full text Add to dashboard Cite

Kan Kültürlerinden İzole Edilen Enterococcus faecium ve ABSTRACT In vitro Daptomycin and Linezolid Susceptibility Profiles of Enterococcus faecium and Enterococcus faecalis Strains Isolated from Blood Cultures Objective: Enterococcal infections are among the leading causes of health care-associated infections, and in the treatment of these infections gradually increasing rate of antimicrobial resistance issue is encountered all over theworld. Resistance to glycopeptides and high-level aminoglycosides also increases the use of antibiotics such as linezolid and daptomycin against resistant gram-positive bacteria. Detection of in vitro efficacies of daptomycin and linezolid against Enterococcus faecium and Enterococcus faecalis strains isolated from blood cultures was aimed in this study Material and Methods

show abstract

In Vitro Activities of Daptomycin, Vancomycin, Linezolid, and Quinupristin-Dalfopristin against Staphylococci and Enterococci, Including Vancomycin- Intermediate and -Resistant Strains

Cited by 328 publications

References 10 publications

Pargamicin A, a Novel Cyclic Peptide Antibiotic from Amycolatopsis sp.

Pargamicin A, a Novel Cyclic Peptide Antibiotic from Amycolatopsis sp.

In vitro Activity of Daptomycin, Linezolid and Rifampicin on Staphylococcus epidermidis Biofilms

In Vitro Daptomycin and Linezolid Susceptibility Profiles of Enterococcus faecium and Enterococcus faecalis Strains Isolated from Blood Cultures

Contact Info

Product

Resources

About